11:38 AM EST - Nuvo Research Inc. : today announced it has received Health Canada approval to conduct a new Phase 2 clinical trial (the 2015 WF10 Trial) to assess WF10 for the treatment of allergic rhinitis. Nuvo Research Inc.
shares T.NRI are trading down $0.11 at $6.09.
